非那雄胺联合M受体拮抗剂治疗前列腺增生合并膀胱过度活动症的疗效

Effect of non finasteride combined with M receptor antagonists in the treatment of benign prostatic hyperplasia with overactive bladder

目的探讨和分析对前列腺增生合并膀胱过度活动症采取非那雄胺联合M受体拮抗剂治疗的临床疗效及价值。方法选取2012年1月～2013年6月接受治疗的前列腺增生合并膀胱过度活动症患者70例为研究对象,均给予非那雄胺联合M受体拮抗剂治疗,观察和对比患者治疗前后IPSS(国际前列腺症状评分)、OABSS(膀胱过度活动症评分)及尿急次数等变化情况。结果治疗后,患者的IPSS评分、OABSS评分均较治疗前明显降低,尿急次数、残余尿量、前列腺体积均较治疗前明显减少;治疗前后各项指标对比差异均有统计学意义(P<0.05)。结论临床上对前列腺增生合并膀胱过度活动症患者给予非那雄胺联合M受体拮抗剂治疗,能明显改善患者前列腺症状,减轻膀胱过度活动症,改善患者前列腺功能及提升生活质量。

Objective To investigate and analyze the hyperplasia of prostate and bladder hyperactive disorder take finasteride combined the clinical curative effect and value of M receptor antagonist treatment.Methods from January 2012 to June 2012 treated 70 cases of hyperplasia of prostate and bladder hyperactive disorder patients as the research object, all give finasteride combined M receptor antagonist treatment, observation and comparison before and after treatment in patients with IPSS（international prostate symptom score）, OABSS bladder hyperactive disorder（score） and urgency number changes. ResultsAfter treatment, the patients of IPSS score, OABSS score was significantly decreased, the number of urgency, residual urine volume, prostate volume was significantly reduced the; Each index contrast differences before and after the treatment are statistically significant.Conclusion Clinical patients with hyperplasia of prostate and bladder hyperactive disorder give finasteride combined M receptor antagonist treatment, can significantly improve symptoms of prostate patients, alleviate bladder excessive activity, improve the function of patients with prostate cancer and improve the quality of life.